A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.

Single arm, multiple-dose study evaluating the use of imsidolimab for the treatment of GPP.

Inclusion Criteria:

• Diagnosis of active GPP
• Japanese Dermatology Association (JDA) severity index total score of at least 6 and erythema with pustules accounting for at least 10% of body surface area or a moderate severity score on Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA)
• Must be candidates for systemic therapy or phototherapy

Exclusion Criteria:

• Erythrodermic, guttate psoriasis, drug induced GPP
• Any other ongoing inflammatory disease that interfere with the Investigator's ability to evaluate the subject's response to therapy
• History of recurrent or chronic infection
• ongoing use of psoriasis prohibited medication

Other protocol-defined inclusion/exclusion criteria may apply